Product
RH5.1
1 clinical trial
1 indication
Indication
MalariaClinical trial
A Phase IIb Randomised Controlled Trial of the Safety, Immunogenicity and Efficacy of the Blood-stage Malaria Vaccine Candidates RH5.1 in Matrix-MTM and RH5.2-VLP in Matrix-MTM in Infants Aged 5-17 Months in Burkina Faso.Status: Recruiting, Estimated PCD: 2024-08-01